Key result
Neuroleptics remain linked to a ~1% risk of neuroleptic malignant syndrome, unchanged over 20 years.
Why the study?
What is the frequency of neuroleptic malignant syndrome in neuroleptic-treated patients?
What is the frequency of neuroleptic malignant syndrome in neuroleptic-treated patients?
Answers are grounded in this paper and cite their sources.
The frequency of neuroleptic malignant syndrome has remained stable at approximately 1% of neuroleptic-treated patients, suggesting the recent surge in reports reflects increased scientific interest rather than a true increase in incidence.
Summary Neuroleptic malignant syndrome, a dangerous complication of neuroleptic treatment, was first reported in the French literature in the 1960’s. Although long assumed to be rare, the syndrome has beat widely reported recently, particularly in the United States. Does this surge of reports reflect a true increase in the frequency of the syndrome, or merely increased scientific interest in the disorder? A review of available epidemiologic data favors the latter possibility: the syndrome probably continues to affect about 1% of neuroleptic-treated patients, a figure little different from the original French estimate more titan 20 years ago.
No takes yet. Share an insight, caveat, or question.
Keck et al. (1987) conducted a review in Neuroleptic malignant syndrome. Neuroleptic treatment was evaluated on Frequency of neuroleptic malignant syndrome. A review of epidemiologic data suggests that neuroleptic malignant syndrome continues to affect about 1% of neuroleptic-treated patients, similar to estimates from over 20 years ago.
Synapse has enriched 10 related papers. Consider them for comparative context: